{"id":746814,"date":"2026-07-06T16:55:09","date_gmt":"2026-07-06T16:55:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/746814\/"},"modified":"2026-07-06T16:55:09","modified_gmt":"2026-07-06T16:55:09","slug":"incyte-completes-vega-therapeutics-acquisition-adding-novel-mab-to-hematology-portfolio","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/746814\/","title":{"rendered":"Incyte Completes Vega Therapeutics Acquisition, Adding Novel mAb to Hematology Portfolio"},"content":{"rendered":"<p class=\"has-background\" style=\"background-color:#bebebe\">Why This Matters: Check out Contract Pharma\u2019s <a href=\"https:\/\/www.contractpharma.com\/exclusives\/2024-pharmaceutical-industry-mergers-acquisitions-roundup\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmaceutical Industry Mergers &amp; Acquisitions Roundup<\/a>.<\/p>\n<p><a href=\"https:\/\/incyte.com\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Incyte<\/a> completed its <a href=\"https:\/\/www.contractpharma.com\/breaking-news\/incyte-agrees-to-acquire-vega-therapeutics-for-1-25b\/\" rel=\"nofollow noopener\" target=\"_blank\">previously announced<\/a>, $1.25 billion upfront acquisition of Vega Therapeutics, a wholly owned subsidiary of <a href=\"https:\/\/star-therapeutics.com\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Star Therapeutics<\/a>.<\/p>\n<p>The transaction adds a novel monoclonal antibody (mAb), VGA039, to Incyte\u2019s hematology portfolio. VGA039 is currently in Phase III development to treat von Willebrand disease (VWD), considered the most common inherited bleeding disorder.<\/p>\n<p>VWD Explained<\/p>\n<p>In VWD, blood does not properly clot; this is caused by low or defective von Willebrand factor (VWF). Approximately 135,000 people in the United States have a diagnosis of VWD. These patients may experience excessive bleeding varying in severity and frequency.<\/p>\n<p>Current treatments include factor replacement therapies that may require multiple weekly intravenous injections. By contrast, VGA039 aims to become the first once-monthly subcutaneous prophylactic therapy for patients with VWD. It modulates Protein S to improve hemostasis, which can potentially improve the body\u2019s ability to control bleeding.<\/p>\n<p>The U.S. FDA already granted VGA039 Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations.<\/p>\n<p class=\"has-text-align-center has-vivid-red-color has-text-color has-link-color wp-elements-1d60e31330caedbcbd2fb79d235436c8\">\u201cVGA039 adds one of the most promising late-stage hematology assets in development to our portfolio.\u201d<\/p>\n<p class=\"has-text-align-center\">Bill Meury, Incyte CEO<\/p>\n<p>Incyte Excited<\/p>\n<p>\u201cVGA039 adds one of the most promising late-stage hematology assets in development to our portfolio,\u201d Incyte CEO Bill Meury said.<\/p>\n<p>Meury touted VGA039\u2019s potential as a first-in-class therapy.<\/p>\n<p>\u201cVGA039 is a strong strategic fit with our hematology franchise and expands our presence into bleeding disorders. Our priority is to advance the Phase III program,\u201d Meury said. \u201cWe look forward to partnering with our talented new colleagues from Vega to progress VGA039 through clinical development.\u201d<\/p>\n<p>More Acquisition Details<\/p>\n<p>Resulting from the acquisition, Star Therapeutics, Vega\u2019s parent, may receive up to $750 million in additional payments for sales milestones. Financially, the transaction will reflect as a one-time R&amp;D expense in Q3 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"Why This Matters: Check out Contract Pharma\u2019s Pharmaceutical Industry Mergers &amp; Acquisitions Roundup. Incyte completed its previously announced,&hellip;\n","protected":false},"author":2,"featured_media":746815,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-746814","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/746814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=746814"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/746814\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/746815"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=746814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=746814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=746814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}